Pharmacogenetics of immunosuppressive drugs: Prospect of individual therapy for transplant patients

Pharmacogenomics

Volumn 9, Issue 5, 2008, Pages 585-596

  Ekbal, Nasirul J ^a   Holt, David W ^a   MacPhee, Iain A M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ABCB1 ciclosporin; CYP3A5; Immunosuppression; Mycophenolate; Pharmacogenetics; Sirolimus; Tacrolimus; Therapeutic drug monitoring; Transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DACLIZUMAB; DRUG METABOLITE; EVEROLIMUS; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; BONE NECROSIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPE; HEART GRAFT; HETEROZYGOSITY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MORNING DOSAGE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TRANSPLANTS;

EID: 44949115018     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.5.585     Document Type: Review

References (120)

1. Lechler RI, Sykes M, Thomson AW, Turka LA: Organ transplantation - how much of the promise has been realized? Nat. Med. 11 (6), 605-613 (2005).
2. Halloran PF: Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351(26), 2715-2729 (2004).
3. Clase CM, Mahalati K, Kiberd BA et al.: Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am. J. Transplant. 2(8), 789-795 (2002).
4. Undre NA, van Hoof J, Christiaans M et al.: Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc. 31, 296-298 (1999).
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326-2333 (2003).
6. Davidson JA, Wilkinson A: New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view. Diabetes Care 27(3), 805-812 (2004).
7. Kahan BD, Napoli KL, Kelly PA et al.: Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transplant. 14(2), 97-109 (2000).
8. Holt DW: Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr. Opin. Nephrol. Hypertens. 11(6), 657-663 (2002).
9. Ng FL, Holt DW, MacPhee IA: Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin. Pharmacother. 8(13), 2045-2058 (2007).
10. Hesselink DA, van Gelder T, van Schaik RH: The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005).
11. Burckart GJ, Liu XI: Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther. Drug Monit. 28(1), 23-30 (2006).
12. Andrews PA, Sen M, Chang RWS: Racial variation in dosage requirements of tacrolimus. Lancet 348(23), 1446 (1996).
13. Neylan JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 65(4), 515-523 (1998).
14. Mancinelli LM, Frassetto L, Floren LC et al.: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69, 24-31 (2001).
15. Vadivel N, Garg A, Holt DW, Chang RW, MacPhee IA: Tacrolimus dose in black renal transplant recipients. Transplantation 83(7), 997-999 (2007).
16. Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE: FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur. J. Immunol. 25(2), 563-571 (1995).
17. Cardenas ME, Lim E, Heitman J: Mutations that perturb cyclophilin A ligand binding pocket confer cyclosporin A resistance in Saccharomyces cerevisiae. J. Biol. Chem. 270(36), 20997-21002 (1995).
18. Brogan IJ, Pravica V, Hutchinson IV: Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl. Immunol. 8(2), 139-141 (2000).
19. Dai Y, Iwanaga K, Lin YS et al.: In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol. 68(9), 1889-1902 (2004).
20. Dai Y, Hebert MF, Isoherranen N et al.: Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 34(5), 836-847 (2006).
21. Kamdem LK, Streit F, Zanger UM et al.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51(8), 1374-1381 (2005).
22. Saeki T, Ueda K, Tanagawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK505. J. Biol. Chem. 268(9), 6077-6080 (1993).
23. Miller DS, Fricker G, Drewe J: P-glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J. Pharmacol. Exp. Ther. 282(1), 440-444 (1997).
24. Zhang Y, Benet LZ: The gut as a barrier to drug absbrption. Combined role of cytochrome P4503A and P-glycoprotein. Clin. Pharmacokinet. 40(3), 159-168 (2001).
25. Tuteja S, Alloway RR, Johnson JA, Gaber AO: The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71(9), 1303-1307 (2001).
26. Gupta SK, Bakran A, Johnson RW, Rowland M: Cyclosporin - erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27(4), 475-481 (1989).
27. MacDonald A, Scarola J, Burke JT, Zimmerman JJ: Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin. Ther. 22(Suppl. B), B101-B121 (2000).
28. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y: Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am. J. Transplant. 5(6), 1383-1391 (2005).
29. Kuehl F, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genetics 27, 383-391 (2001).
30. Fredericks S, Moreton M, MacPhee IA et al.: Genotyping cytochrome P450 3A5 using the Light Cycler. Ann. Clin. Biochem. 42(Pt 5), 376-381 (2005).
31. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059-1069 (2004).
32. Choudhuri S, Klaassen CD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25(4), 231-259 (2006).
33. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
34. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15(10), 693-704 (2005).
35. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
36. Chowbay B, Li H, David M, Cheung YB, Lee EJ: Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol. 60(2), 159-171 (2005).
37. MacPhee IAM, Fredericks S, Tai T et al.; Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
38. MacPhee IA, Fredericks S, Tai T et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6), 914-919 (2004).
39. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
40. Thervet E, Anglicheau D, King B et al.: Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233-1235 (2003).
41. Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDRR1 (ABCBI) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
42. MacPhee IA, Fredericks S, Mohamed M et al.: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose normalized tacrolimus blood concentrations in whites and south Asians. Transplantation 79(4), 499-502 (2005).
43. Roy JN, Barama A, Poirier C, Vinet B, Roger M: CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16(9), 659-665 (2006).
44. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
45. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL: Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J. Clin. Pharm. Ther. 32(5), 505-515 (2007).
46. Kolars JC, Lown KS, Schmiedlin-Ren P et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4(5), 247-259 (1994).
47. Schuetz EG, Schuetz JD, Grogan WM et al.: Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys. 294(1), 206-214 (1992).
48. Givens RC, Lin YS, Dowling AL et al.: CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95(3), 1297-1300 (2003).
49. Asghar A, Gorski JC, Haehner-Daniels B, Hall SD: Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab. Dispos. 30(1), 20-26 (2002).
50. Masuda S, Coto M, Fukatsu S et al.: Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther. 79(1), 90-102 (2006).
51. Fredericks S, Moreton M, Reboux S et al.: multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 82(5), 705-708 (2006).
52. Elens L, Capron A, Kerckhove VV et al.: 1199G>A and 2677G>T /A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 17(10), 873-883 (2007).
53. Masuda S, Inui K: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther. 112(1), 184-198 (2006).
54. Eng HS, Mohamed Z, Calne R et al.: The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 69(10), 1858-1864 (2006).
55. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J: The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14(10), 665-671 (2004).
56. 2 measurements. Clin. Transplant. 21(2), 252-257 (2007).
57. Foote CJ, Greer W, Kiberd B et al.: Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantatian 83(10), 1380-1384 (2007).
58. Barnard JB, Richardson S, Sheldon S et al.: The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 82 (12), 1677-1682 (2006).
59. Hauser IA, Schaeffeler E, Gauer S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16(5), 1501-1511 (2005).
60. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF: Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 25(6), 779-789 (2005).
61. Hebert MF, Dowling AL, Gierwatowski C et al.: Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13(11), 661-674 (2003).
62. Anglicheau D, Pallet N, Rabant M et al.: Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int. 70(6), 1019-1025 (2006).
63. Aoyama T, Yamano S, Waxman DJ et al.: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264(18), 10388-10395 (1989).
64. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A: Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin. Chem. 36(8 Pt 1), 1510-1516 (1990).
65. Bader A, Hansen T. Kirchner G, Allmeling C, Haverich A, Borlak JT: Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br. J. Pharmacol. 129(2), 331-342 (2000).
66. Iwasaki K, Shiraga T, Matsuda H et al.: Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab. Dispos. 23 (1), 28-34 (1995).
67. Moreton M, Fredericks S, McKeown DA et al.: CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay. Clin. Chem. 51(11), 2214-2215 (2005).
68. 1 values and impact of CYP3A5 expression. Drug Metab. Dispos. 27(2), 180-187 (1999).
69. Yu KS, Cho JY, Jang IJ et al.: Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin. Pharmacol. Ther. 76(2), 104-112 (2004).
70. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT: Differented inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98(1), 79-85 (2006).
71. Anglicheau D, le Corre D, Lechaton S et al.: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. 5(3), 595-603 (2005).
72. le Meur Y, Djebli N, Szelag JC et al.: CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80(1), 51-60 (2006).
73. Mourad M, Mourad G, Wallemacq P et al.: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80(7), 977-984 (2005).
74. Renders L, Frisman M, Ufer M et al.: CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin. Pharmacol. Ther. 81(2), 228-234 (2007).
75. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics 16(2), 119-127 (2006).
76. Wei-lin W, Jing I Shu-sen Z et al.: Tacrolimus dose requirement in relation to. donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 12(5), 775-780 (2006).
77. Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14(7), 471-478 (2004).
78. Masuda S, Goto M, Fukatsu S et al.: Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pbarmacol. Ther. 79(1), 90-102 (2006).
79. Higgins RM, Morlidge C, Magee P, McDiarmaid-Gordon A, Lam FT, Kashi H: Conversion between cyclosporin and tacrolimus-30-fold dose prediction. Nephrol. Dial. Tansplant. 14(6), 1609 (1999).
80. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD: The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin. Pharmacol. Ther. 63(1), 48-53 (1998).
81. Ciancio G, Burke GW, Gaynor JJ et al.: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 77(2), 244-251 (2004).
82. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A: Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant. Proc. 38(10), 3456-3458 (2006).
83. Picard N, Djebli N, Sauage FL, Marquet P: Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab. Dispos. 35(3), 350-355 (2007).
84. Sonneveld P, Durie BG, Lokhorst HM et al.: Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340(8814), 255-259 (1992).
85. Zheng H, Schuetz E, Zeevi A et al.: Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J. Clin. Pharmacol. 45(4), 404-410 (2005).
86. Asano T, Takahashi KA, Fujioka M et al.: ABCB1 C3435t and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13(11), 675-682 (2003).
87. Asano T, Takahashi KA, Fujioka M. et al.: Genetic analysis of steroid-induced osteonecrosis of the femoral head. J. Orthop. Sci. 8(3), 329-333 (2003).
88. Leung DY, Hamid Q, Vottero A et al.: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. J Exp. Med. 186(9), 1567-1574 (1997).
89. Honda M, Orii F, Ayabe T et al.: Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118(5), 859-866 (2000).
90. Kino T, de Martino MU, Charmandati E, Mirani M, Chrousos GP: Tissue glucocorticoid resistance/hypersensitivity syndromes. J. Steroid Biochem. Mol. Biol. 85(2-5), 457-467 (2003).
91. Chan GL, Erdmann GR, Gruber SA, Maras AJ, Canafax DM: Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 30(4), 358-363 (1990).
92. Evans WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26(2), 186-191 (2004).
93. Yates CR, Krynetski EY, Loennechen T et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997).
94. Song DK, Zhao J, Zhang LR: TMPT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. J. Clin. Pharm. Ther. 31(6), 627-635 (2006).
95. Salvadori M, Holzer H, de Mattos A et al.: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. 4(2), 231-236 (2004).
96. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268(36), 27286-27290 (1993).
97. Zimmermann AC, Wright KL, Ting JP, Mitchell BS: Regulation of inosine-5′-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5′ palindromic octamer sequence. J. Biol. Chem. 272(36), 22913-22923 (1997).
98. Glander P, Hambach P, Braun, KP et al.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. 4(12), 2045-2051 (2004).
99. Wang J, Zeevi A, Webber S et al.: A novel variant L263F in human inosine 5′ monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17(4), 283-290 (2007).
100. Farazi T, Leichman J, Harris T, Cahoon M, Hedstrom L: Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5′-monophosphate dehydrogenase. J. Biol. Chem. 272(2), 961-965 (1997).
101. Wang J, Yang JW, Zeevi A et al.: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
102. Hesselink DA, van Gelder T: Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin. Pharmacol. Ther. 78(4), 317-321 (2005).
103. Hesselink DA, van Hest RM, Mathot RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. 5(5), 987-994 (2005).
104. Girard H, Court MH, Bernard O et al.: Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14(8), 501-515 (2004).
105. Bernard O, Guillemette C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32(8), 775-778 (2004).
106. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78(4), 351-361 (2005).
107. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11(2), 175-184 (2001).
108. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y: Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8), 1074-1084 (2006).
109. Satoh S, Tada H, Murakami M et al.: Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82(4), 486-493 (2006).
110. Anglicheau D, Flamant M, Schlageter MH et al.: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant. 18(11), 2409-2414 (2003).
111. Kawasaki S, Makuuchi M, Ishizone S, Matsunami H, Terada M, Kawarazaki H: Liver regeneration in recipients and donors after transplantation. Lancet 339(8793), 580-581 (1992).
112. Inomata Y, Kiuchi T, Kim I et al.: Auxiliary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients: Transplantation 67(10), 1314-1319 (1999).
113. Dowling TC, Briglia AE, Fink JC et al.: Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. 73(5), 427-434 (2003).
114. Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V: Downregulation of intestinal cytochrome p450 in chronic renal failure. J. Am. Soc. Nephrol. 13(6), 1579-1585 (2002).
115. Kuypers DR, Vanrenterghem Y, Squifflet JP et al.: Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit. 25(5), 609-622 (2003).
116. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, di Rienzo A: Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J. 6(2), 105-114 (2006).
117. Anglicheau D, Verstuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003).
118. Mueller TF, Einecke G, Reeve J et al.: Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am. J. Transplant. 7(12), 2712-2722 (2007).
119. Deng MC, Eisen HJ, Mehra MR et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6(1), 150-160 (2006).
120. Horwitz PA, Tsai EJ, Putt ME et al.: Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110(25), 3815-3821 (2004).